Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.06p +0.98% 6.20p 6.12p 6.18p 6.20p 6.18p 6.18p 593,316 12:02:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.0 -15.3 -3.2 - 32.64

Vernalis Share Discussion Threads

Showing 3176 to 3195 of 3825 messages
Chat Pages: Latest  129  128  127  126  125  124  123  122  121  120  119  118  Older
DateSubjectAuthorDiscuss
05/8/2016
08:43
I'm surprised the share price hasn't responded more positively, given that most of the sales for new products will be in dollars.Let's hope the summer cough and cold market has been booming in the US.
fhmktg
26/7/2016
13:42
Buying continues!
fhmktg
26/7/2016
13:18
Vote of continued support from Woodford!
fhmktg
14/7/2016
12:59
Looks like we may have bottomed out folks.
investordave
13/7/2016
16:21
I saw this as having some confidence that either the current supplier site would continue or a deal to transfer the site of manufacture, which would take some deal with the FDAEither way some market feedback as to how receptive the key prescribers are could help?
fhmktg
13/7/2016
15:34
fhmktg I see the following 19 May 2016 The following lines are worrying: Whilst the launch of Moxatag(R) will still occur this summer, the uncertainty over further supply will impact Vernalis' additional promotion of Moxatag(R). I believe we are in the summer and the company should be telling us what is happening in relation to supplies. 19 May 2016 LSE: VER Moxatag Supply Update Vernalis plc ("Vernalis" or the "Company") was informed yesterday that Suir Pharma Limited ("Suir") of Clonmel Ireland, the sole source supplier of finished dosage form Moxatag(R), has been placed into Provisional Liquidation. Information is limited at this time, but the liquidator has indicated that it intends to seek a purchaser for the business as a going concern. Suir has already supplied launch stocks of Moxatag(R) to Vernalis, which are currently stored at Vernalis' third party warehouse in the US and are available for supply to wholesaler customers. The timing of further supplies is now uncertain as Suir is currently the only approved supplier under the Moxatag(R) NDA. Whilst the launch of Moxatag(R) will still occur this summer, the uncertainty over further supply will impact Vernalis' additional promotion of Moxatag(R). This additional promotion will now occur when there is more certainty over the timing of routine ongoing supply. This will not have a material impact on our financial position or our trading results for the financial years ending 30 June 2016 and 2017. The Company expects to provide a further update on publication of its financial results for the year ended 30 June 2016. - Ends -
twodegrees
12/7/2016
17:21
See the May 19th RNS.
fhmktg
12/7/2016
16:50
fhmktg, surely the company should be giving us an update on what is going on.
twodegrees
11/7/2016
09:00
Could be possible to move Moxatag to Saneca the Suir previous owner over a time period, given they have all the data on the product but would need FDA approval. Could be expedited with commitment from both parties.
fhmktg
08/7/2016
11:10
September for news on the supply chain I believe?
fhmktg
08/7/2016
10:14
fhmktg, this was recovering very well in fact had hit new highs and has been walked all the way back down because of possible supply issues. I am annoyed that the company has not given any indication yet if the supply chain has been sorted and that has contributed to a share price fall of over 505 in 4 months...so I tend to disagree that progress is being made. I f we have a product and cannot get it to market...then ????????
twodegrees
08/7/2016
08:13
Slow but steady progress towards a new company, but it's a 4-5 year timeframe.Not sure how the share price will evolve.Any thoughts or predictions?
fhmktg
09/6/2016
16:24
well spotted, now in the header - I'll tidy it up later
bountyhunter
09/6/2016
16:16
director buys x 2 and it falls...woops
twodegrees
09/6/2016
16:04
Good sign when ceo and cfo buy shares, underpins confidence!
fhmktg
20/5/2016
18:22
Beat me to it, thinking the same thing...So why?
ffp
20/5/2016
15:29
with all the money that vernalis raised why don't they buy it
twodegrees
20/5/2016
08:57
Nice little set up in Clonmel. Two units, one dedicated to beta lac tam antibiotics and the other set up and registered for a range of products including restricted items- presumably opiates.I'm sure there will be interested folk out there,but whether it has enough capacity to be viable?
fhmktg
20/5/2016
07:54
It seems like the business will be kept going for now, so its certainly not an immediate fire sale liquidation (see link) http://www.irishtimes.com/business/health-pharma/more-than-130-jobs-at-risk-at-tipperary-s-suir-pharma-1.2650705 However, I'm surprised that Vernalis went with just one supplier in the NDA, it is normal industry practice to register at least two suppliers for the AS, this implies a lack of forward thinking and/or poor risk assessment from the Vernalis management.
timbo003
20/5/2016
07:33
If the business is sold as a going concern then no problem. The administrators will be keen to keep ongoing customers either by continuing to supply product while a buyer is sought or factoring in future business from VRN in the sale value. Suggest this is a market over-reaction.
zipstuck
Chat Pages: Latest  129  128  127  126  125  124  123  122  121  120  119  118  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180920 14:59:36